{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:08:01Z","timestamp":1791994081525,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcp.2018.07.047","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T21:48:12Z","timestamp":1533160092000},"page":"304-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis"],"prefix":"10.1016","volume":"157","author":[{"given":"Adela","family":"Garc\u00eda-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Garrido-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L.","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Appendino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Calzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bcp.2018.07.047_b0005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/jid.2012.67","article-title":"Toward personalized medicine in scleroderma: classification of scleroderma patients into stable \u201cinflammatory\u201d and \u201cfibrotic\u201d subgroups","volume":"132","author":"Leask","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2018.07.047_b0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The pathogenesis of systemic sclerosis","volume":"6","author":"Katsumoto","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5152\/eurjrheum.2017.17025","article-title":"The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease","volume":"4","author":"Barrie","year":"2017","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.bcp.2018.07.047_b0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/bs.apha.2017.03.008","article-title":"The role of nuclear hormone receptors in cannabinoid function","volume":"80","author":"Pistis","year":"2017","journal-title":"Adv. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.047_b0030","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/kep189","article-title":"Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts","volume":"48","author":"Garcia-Gonzalez","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.bcp.2018.07.047_b0035","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/art.27642","article-title":"Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis","volume":"62","author":"Marquart","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0040","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.24395","article-title":"The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.047_b0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2353\/ajpath.2010.090763","article-title":"Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis","volume":"177","author":"Servettaz","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1189\/jlb.71.3.388","article-title":"The role of PPARs in inflammation and immunity","volume":"71","author":"Clark","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bcp.2018.07.047_b0055","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/124624","article-title":"The role of PPAR gamma in systemic sclerosis","volume":"2015","author":"Dantas","year":"2015","journal-title":"PPAR Res."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0060","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.bcp.2018.07.047_b0065","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3803\/EnM.2017.32.1.115","article-title":"Lobeglitazone, a novel peroxisome proliferator-activated receptor gamma agonist, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice","volume":"32","author":"Bae","year":"2017","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"5","key":"10.1016\/j.bcp.2018.07.047_b0070","doi-asserted-by":"crossref","first-page":"L891","DOI":"10.1152\/ajplung.00333.2007","article-title":"PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis","volume":"294","author":"Milam","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.047_b0075","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2018.07.047_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/srep21703","article-title":"The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways","volume":"6","author":"del R\u00edo","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.047_b0085","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.047_b0090","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0095","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/ard.2010.137539","article-title":"The cannabinoid WIN55, 212\u20132 abrogates dermal fibrosis in scleroderma bleomycin model","volume":"70","author":"Balistreri","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2018.07.047_b0100","article-title":"Potent anti-inflammatory and pro-resolving effects of anabasum in a human model of self-resolving acute inflammation","author":"Motwani","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2018.07.047_b0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12974-018-1103-y","article-title":"Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy","volume":"15","author":"Navarrete","year":"2018","journal-title":"J. Neuroinflam."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0115","doi-asserted-by":"crossref","DOI":"10.2144\/000112729","article-title":"Standardized quantification of pulmonary fibrosis in histological samples","volume":"44","author":"Hubner","year":"2008","journal-title":"Biotechniques"},{"issue":"15","key":"10.1016\/j.bcp.2018.07.047_b0120","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Meth."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0130","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.bcp.2018.07.047_b0135","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.bcp.2018.07.047_b0140","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"issue":"6","key":"10.1016\/j.bcp.2018.07.047_b0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0150","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1046\/j.1523-1747.1999.00528.x","article-title":"Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma","volume":"112","author":"Yamamoto","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bcp.2018.07.047_b0155","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/270938","article-title":"Vascular changes in bleomycin-induced scleroderma","volume":"2011","author":"Yamamoto","year":"2011","journal-title":"Int. J. Rheumatol."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.047_b0160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.047_b0165","first-page":"2628","article-title":"Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W\/W(V) mice","volume":"26","author":"Yamamoto","year":"1999","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0170","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.047_b0175","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2018.07.047_b0180","article-title":"The role of extracellular matrix components in angiogenesis and fibrosis: possible implication for Systemic Sclerosis","volume":"1\u201311","author":"Liakouli","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrrheum.2016.99","article-title":"Systemic sclerosis: tenascin C perpetuates tissue fibrosis","volume":"12","author":"Ummarino","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nrrheum.2016.212","article-title":"Connective tissue disease: reflections on the EULAR recommendations for the treatment of systemic sclerosis","volume":"13","author":"Pope","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.047_b0195","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1096\/fj.08-128736","article-title":"Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator","volume":"23","author":"Ghosh","year":"2009","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.047_b0200","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mcn.2008.10.015","article-title":"A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules","volume":"40","author":"Mestre","year":"2009","journal-title":"Mol. Cell. Neurosci."},{"issue":"9","key":"10.1016\/j.bcp.2018.07.047_b0205","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.19.9.2094","article-title":"Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction","volume":"19","author":"Jackson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","article-title":"Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators","volume":"101","author":"Pasceri","year":"2000","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.bcp.2018.07.047_b0215","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1096\/fasebj.9.10.7542214","article-title":"Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers","volume":"9","author":"Collins","year":"1995","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.047_b0220","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/jpet.107.131896","article-title":"Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats","volume":"324","author":"Munoz-Luque","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0225","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm.1987","article-title":"Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease","volume":"15","author":"Midwood","year":"2009","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.047_b0230","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/labinvest.2009.45","article-title":"PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway","volume":"89","author":"Ji","year":"2009","journal-title":"Lab. Invest."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0235","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bcp.2018.07.047_b0240","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/1523-1747.ep12331160","article-title":"IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts","volume":"107","author":"Makhluf","year":"1996","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0245","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.jid.5700090","article-title":"Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase\/Akt and the protein kinase C signaling pathways","volume":"126","author":"Jinnin","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0250","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/jcmm.12028","article-title":"Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis","volume":"17","author":"Manetti","year":"2013","journal-title":"J. Cell Mol. Med."},{"issue":"10","key":"10.1016\/j.bcp.2018.07.047_b0255","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1161\/01.ATV.0000282198.60701.94","article-title":"Platelet-derived growth factor receptor-beta constitutive activity promotes angiogenesis in vivo and in vitro","volume":"27","author":"Magnusson","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2018.07.047_b0260","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1097\/01.LAB.0000107160.81875.33","article-title":"VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model","volume":"83","author":"Nakatsu","year":"2003","journal-title":"Lab. Invest."},{"issue":"2","key":"10.1016\/j.bcp.2018.07.047_b0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/gb-2005-6-2-209","article-title":"The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease","volume":"6","author":"Holmes","year":"2005","journal-title":"Genome Biol."},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2018.07.047_b0270","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar2186","article-title":"How does endothelial cell injury start? The role of endothelin in systemic sclerosis","volume":"9","author":"Abraham","year":"2007","journal-title":"Arthritis Res. Ther."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2018.07.047_b0275","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000163802","article-title":"situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease","volume":"61","author":"Koch","year":"1993","journal-title":"Pathobiology"},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0280","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/rheumatology\/kep091","article-title":"The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1","volume":"48","author":"Rabquer","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.bcp.2018.07.047_b0285","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/cr.2009.5","article-title":"TGF-beta-induced epithelial to mesenchymal transition","volume":"19","author":"Xu","year":"2009","journal-title":"Cell Res."},{"issue":"8","key":"10.1016\/j.bcp.2018.07.047_b0290","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/art.39658","article-title":"Identification of optimal mouse models of systemic sclerosis by interspecies comparative genomics","volume":"68","author":"Sargent","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0295","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1172\/JCI117154","article-title":"Elevated expression of type VII collagen in the skin of patients with systemic sclerosis. Regulation by transforming growth factor-beta","volume":"93","author":"Rudnicka","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bcp.2018.07.047_b0300","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ajpath.2011.11.024","article-title":"Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets","volume":"180","author":"Greenblatt","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.bcp.2018.07.047_b0305","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bcp.2018.07.047_b0310","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor beta as a therapeutic target in systemic sclerosis","volume":"5","author":"Varga","year":"2009","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295218303174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:04:00Z","timestamp":1757768640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295218303174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":62,"alternative-id":["S0006295218303174"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.047","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2018.07.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}